TNF and cancer: CD treatment is based on the use of immunosuppressors, which do not seem to increase the risk of developing cancer, beside a slightly increased risk of lymphoproliferative and cutaneous malignancies associated with thiopurines and tumor necrosis factor (TNF) antagonists [18].